BioVentures Investors

Georgiamune is an immunotherapy company dedicated to advancing oncology treatments. The firm specializes in next-generation immunotherapeutic and homeostatic therapies aimed at addressing cancer and autoimmune diseases. By focusing on innovative approaches, Georgiamune seeks to enhance patient recovery from cancer, contributing to significant breakthroughs in the field of immunotherapy.

BRAINBox Solutions, Inc. is a medical technology company based in Richmond, Virginia, that specializes in developing tests for diagnosing and prognosticating mild traumatic brain injury (TBI). Founded in 2002, the company employs a multi-modality approach that integrates blood biomarker panels, neurocognitive assessments, and point-of-care instruments to deliver objective evidence of TBI and predict patient recovery outcomes. Its innovative platform combines injury-related blood protein biomarkers with computerized neurological evaluations, allowing healthcare providers to enhance diagnostic accuracy and improve patient care.

SonoMotion Inc. is a medical device company focused on developing non-invasive solutions for kidney stone disease. Founded in 2012 and based in San Mateo, California, the company offers innovative products such as Break Wave, which safely fragments large kidney stones, and Stone Clear, which aids in clearing the resulting stone fragments within 15 minutes in an office setting, without the need for general anesthesia or X-ray radiation. SonoMotion is actively involved in advancing its technology, with a stone repositioning solution currently undergoing clinical trials and a second-generation stone-breaking technology in development. The company's mission is to provide effective and cost-efficient treatments for kidney stone patients.

Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in biotechnology. It specializes in antibody-based drugs that enhance immune system function, along with providing technical consultation and drug quality inspection services. By focusing on these areas, Kanova aims to help clients improve drug quality and advance the discovery of new biomedicine efficiently.

Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.

Unified Information Devices, Inc. specializes in the development and manufacturing of laboratory animal identification solutions, which include implantable transponders, microchips, external transponders, readers, and customized software. Founded in 2014 and located in Lake Villa, Illinois, the company focuses on optimizing the identification of animals, vials, and cages through its innovative products. UID's offerings utilize RFID technology and the pi software suite, enabling advanced data collection for various research needs, such as body weight measurement and blood sampling. This technology allows researchers to generate accurate and consistent data efficiently.

CoNextions Medical, Inc. is a medical technology company based in Salt Lake City, Utah, that specializes in manufacturing tendon repair surgical equipment. Founded in 2011, the company offers its flagship product, CoNextionsTR, which is an innovative implant made of stainless steel and ultra-high molecular weight polyethylene. This implant is specifically designed to address tendon injuries by providing an alternative to traditional suture repair techniques. CoNextionsTR is tailored for tendons that are 1-4mm thick and 3-7mm wide, aiming to enhance the safety, strength, and durability of tendon repairs. By focusing on reducing complications and improving rehabilitation outcomes, CoNextions Medical is committed to advancing patient care and the economics of tendon repair on a global scale.

POC Medical Systems specializes in developing diagnostic tools focused on breast cancer treatment. The company has created an innovative microfluidic platform that facilitates rapid, point-of-care serum screening. This technology employs antibodies to detect specific biomarkers associated with breast cancer, allowing healthcare providers to make timely and informed decisions regarding patient care. By enabling testing to occur near or at the site of patient care, POC Medical Systems aims to improve the course of treatment for cancer patients through efficient and effective diagnostics.

Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.

Nano-Micro Technology manufactures monodisperse particles in a range of sizes and serves a variety of industries and applications. They provide solutions such as configurable resin development and purification process development. The company's contact modes are phone and physical address.

InSeal Medical Ltd. is a company based in Caesarea, Israel, specializing in the development and manufacturing of percutaneous vascular closure devices. The company’s flagship product, the InSeal intravascular closure device, is designed to effectively seal puncture sites resulting from medical procedures that utilize large bore sheaths. This innovative technology employs an internal biodegradable membrane that adheres to the vessel wall, supported by a self-expandable frame. By facilitating the closure of punctures in vessels ranging from 6 to 10 millimeters in diameter, InSeal Medical aims to enhance patient safety and improve recovery outcomes in vascular procedures. The company operates as a subsidiary of E-Pacing Inc.

Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.

HydroCision, Inc. is a medical device company based in North Billerica, Massachusetts, established in 1994. It specializes in the development and manufacturing of fluid jet surgical tools tailored for minimally invasive spine surgery. The company’s primary offerings include the SpineJet HydroDiscectomy System, which allows for the safe removal of tissue during discectomy procedures without thermal damage, and the TenJet System, designed for ultrasound-guided treatments of chronic tendon pain in various applications such as the shoulder and knee. HydroCision also provides the SpineJet Fusion System for preparing intervertebral disc spaces for graft implantation and the AlloJet system for debridement of donor bones. The company serves hospitals and physicians through its sales representatives, aiming to improve surgical outcomes by leveraging its proprietary water-jet technology. HydroCision was previously known as Surgijet Corporation until its name change in November 1996.

Claros Diagnostics, Inc. develops innovative products aimed at transforming in-vitro medical diagnostic testing by making it accessible outside of laboratory settings. The company has created a handheld immunoassay system designed for point-of-care blood testing, which includes a portable analyzer and a disposable cassette capable of assessing multiple biomarkers. This system facilitates the testing of various medical conditions, including infectious diseases, cancer, and immune disorders, empowering both physicians and patients with timely diagnostic capabilities.

Hydra Biosciences is a biopharmaceutical company located in Cambridge, Massachusetts, focused on developing innovative drugs for pain, inflammation, cardiovascular diseases, and other conditions. The company utilizes its expertise in novel ion channels, specifically targeting Transient Receptor Potential (TRP) ion channels, to create selective and safer therapeutic options. Hydra employs proprietary high-throughput screening platforms that facilitate the identification and development of drug candidates aimed at addressing significant unmet medical needs. With a strong intellectual property portfolio and a flexible approach to drug discovery, Hydra differentiates itself from traditional biopharmaceutical firms. The company has attracted substantial financing from notable investors, enabling it to advance its drug development programs effectively.

Hydra Biosciences is a biopharmaceutical company located in Cambridge, Massachusetts, focused on developing innovative drugs for pain, inflammation, cardiovascular diseases, and other conditions. The company utilizes its expertise in novel ion channels, specifically targeting Transient Receptor Potential (TRP) ion channels, to create selective and safer therapeutic options. Hydra employs proprietary high-throughput screening platforms that facilitate the identification and development of drug candidates aimed at addressing significant unmet medical needs. With a strong intellectual property portfolio and a flexible approach to drug discovery, Hydra differentiates itself from traditional biopharmaceutical firms. The company has attracted substantial financing from notable investors, enabling it to advance its drug development programs effectively.

Verax Biomedical, Incorporated is a medical products company focused on developing rapid tests for detecting bacterial contamination in blood cells and tissues intended for transplantation and cellular therapies. Founded in 1999 and based in Marlborough, Massachusetts, the company addresses a critical need in the field of transfusion medicine, as traditional testing primarily targets viral contaminants, leaving bacterial risks largely unaddressed. Bacteria can proliferate in stored cellular materials, potentially growing from negligible levels at the time of collection to dangerous levels by the time of transfusion or transplantation. Verax Biomedical’s offerings include platelet and red cell Pan Genera Detection tests, designed to identify shared antigens found on various gram-positive and gram-negative bacteria. These tests enable blood banks to effectively detect and mitigate the risks associated with bacterial contamination, thereby enhancing the safety of blood transfusions and cellular therapies.

Cardiosolutions, Inc. specializes in developing innovative medical devices to address mitral regurgitation, a condition affecting the heart's mitral valve. The company's flagship product, the Mitra-Spacer, is a reversible implantable device designed to create a sealing surface for the mitral valve leaflets, effectively reducing or eliminating mitral regurgitation. This technology offers a less invasive alternative to traditional open-heart surgical procedures, catering to patients of various ages, including those experiencing moderate to severe mitral regurgitation and those in congestive heart failure. Founded in 2005 and based in West Bridgewater, Massachusetts, Cardiosolutions aims to enhance patient recovery times and reduce treatment costs through its advanced valve technology.

Verax Biomedical, Incorporated is a medical products company focused on developing rapid tests for detecting bacterial contamination in blood cells and tissues intended for transplantation and cellular therapies. Founded in 1999 and based in Marlborough, Massachusetts, the company addresses a critical need in the field of transfusion medicine, as traditional testing primarily targets viral contaminants, leaving bacterial risks largely unaddressed. Bacteria can proliferate in stored cellular materials, potentially growing from negligible levels at the time of collection to dangerous levels by the time of transfusion or transplantation. Verax Biomedical’s offerings include platelet and red cell Pan Genera Detection tests, designed to identify shared antigens found on various gram-positive and gram-negative bacteria. These tests enable blood banks to effectively detect and mitigate the risks associated with bacterial contamination, thereby enhancing the safety of blood transfusions and cellular therapies.

Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.

Spirus Medical is a developer of advanced care medical devices for the gastrointestinal and cardiovascular markets. The company’s product portfolio includes the Endo-Ease Discovery and Dexterity Steerable Introducer.

Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.

Claros Diagnostics, Inc. develops innovative products aimed at transforming in-vitro medical diagnostic testing by making it accessible outside of laboratory settings. The company has created a handheld immunoassay system designed for point-of-care blood testing, which includes a portable analyzer and a disposable cassette capable of assessing multiple biomarkers. This system facilitates the testing of various medical conditions, including infectious diseases, cancer, and immune disorders, empowering both physicians and patients with timely diagnostic capabilities.

Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.

Verax Biomedical, Incorporated is a medical products company focused on developing rapid tests for detecting bacterial contamination in blood cells and tissues intended for transplantation and cellular therapies. Founded in 1999 and based in Marlborough, Massachusetts, the company addresses a critical need in the field of transfusion medicine, as traditional testing primarily targets viral contaminants, leaving bacterial risks largely unaddressed. Bacteria can proliferate in stored cellular materials, potentially growing from negligible levels at the time of collection to dangerous levels by the time of transfusion or transplantation. Verax Biomedical’s offerings include platelet and red cell Pan Genera Detection tests, designed to identify shared antigens found on various gram-positive and gram-negative bacteria. These tests enable blood banks to effectively detect and mitigate the risks associated with bacterial contamination, thereby enhancing the safety of blood transfusions and cellular therapies.

Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.

Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.

Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.

Hydra Biosciences is a biopharmaceutical company located in Cambridge, Massachusetts, focused on developing innovative drugs for pain, inflammation, cardiovascular diseases, and other conditions. The company utilizes its expertise in novel ion channels, specifically targeting Transient Receptor Potential (TRP) ion channels, to create selective and safer therapeutic options. Hydra employs proprietary high-throughput screening platforms that facilitate the identification and development of drug candidates aimed at addressing significant unmet medical needs. With a strong intellectual property portfolio and a flexible approach to drug discovery, Hydra differentiates itself from traditional biopharmaceutical firms. The company has attracted substantial financing from notable investors, enabling it to advance its drug development programs effectively.

Angiolink Corporation offers EVS vascular closure system, an arterial stapling device for use in closing holes and punctures made in arteries in connection with the catheter-based surgical procedures, such as angioplasty and angiograms.

Verax Biomedical, Incorporated is a medical products company focused on developing rapid tests for detecting bacterial contamination in blood cells and tissues intended for transplantation and cellular therapies. Founded in 1999 and based in Marlborough, Massachusetts, the company addresses a critical need in the field of transfusion medicine, as traditional testing primarily targets viral contaminants, leaving bacterial risks largely unaddressed. Bacteria can proliferate in stored cellular materials, potentially growing from negligible levels at the time of collection to dangerous levels by the time of transfusion or transplantation. Verax Biomedical’s offerings include platelet and red cell Pan Genera Detection tests, designed to identify shared antigens found on various gram-positive and gram-negative bacteria. These tests enable blood banks to effectively detect and mitigate the risks associated with bacterial contamination, thereby enhancing the safety of blood transfusions and cellular therapies.

Ardais Corporation is a clinical genomics company, is dedicated to enhancing and accelerating biomedical research by introducing actual human disease into the pharmaceutical discovery research process. To achieve its goals, Ardais has incorporated multi-disciplinary scientific expertise into its operations, including pathology, molecular biology and genomics, statistical genomics, bioinformatics and medical informatics, as well as process management skills such as logistics, industrial engineering, and robotics. The result of this unique integration is a state-of-the-art, proprietary discovery platform that is dramatically transforming genomic research and leading the way to novel diagnostic and therapeutic solutions.

Pintex Pharmaceuticals, Inc. is a private pharmaceutical company based in Watertown, Massachusetts, dedicated to the discovery and development of innovative cancer therapeutics. Established in May 1999 by Dr. Kun Ping Lu, Dr. Walter Gilbert, and Dr. Janusz Sowadski, the company focuses on the phosphate-specific proline isomerase Pin1 enzyme, which plays a crucial role in cancer progression. The research and development initiatives at Pintex are rooted in groundbreaking work conducted at the Salk Institute for Biological Studies and Harvard University, leveraging patented technologies to advance therapeutic solutions for cancer.

Angiolink Corporation offers EVS vascular closure system, an arterial stapling device for use in closing holes and punctures made in arteries in connection with the catheter-based surgical procedures, such as angioplasty and angiograms.

Verax Biomedical, Incorporated is a medical products company focused on developing rapid tests for detecting bacterial contamination in blood cells and tissues intended for transplantation and cellular therapies. Founded in 1999 and based in Marlborough, Massachusetts, the company addresses a critical need in the field of transfusion medicine, as traditional testing primarily targets viral contaminants, leaving bacterial risks largely unaddressed. Bacteria can proliferate in stored cellular materials, potentially growing from negligible levels at the time of collection to dangerous levels by the time of transfusion or transplantation. Verax Biomedical’s offerings include platelet and red cell Pan Genera Detection tests, designed to identify shared antigens found on various gram-positive and gram-negative bacteria. These tests enable blood banks to effectively detect and mitigate the risks associated with bacterial contamination, thereby enhancing the safety of blood transfusions and cellular therapies.

Pintex Pharmaceuticals, Inc. is a private pharmaceutical company based in Watertown, Massachusetts, dedicated to the discovery and development of innovative cancer therapeutics. Established in May 1999 by Dr. Kun Ping Lu, Dr. Walter Gilbert, and Dr. Janusz Sowadski, the company focuses on the phosphate-specific proline isomerase Pin1 enzyme, which plays a crucial role in cancer progression. The research and development initiatives at Pintex are rooted in groundbreaking work conducted at the Salk Institute for Biological Studies and Harvard University, leveraging patented technologies to advance therapeutic solutions for cancer.

Phase Forward is a prominent provider of integrated data management solutions specifically designed for clinical trials and drug safety. Founded in 1997 by Paul Bleicher, M.D., Ph.D., the company aimed to transition life sciences organizations from traditional paper-based methods to innovative, Internet-enabled solutions. Its flagship product, InForm, has significantly advanced electronic data capture, transforming how clinical data is collected, analyzed, and managed. Phase Forward's technology and global services facilitate the automation and integration of the clinical development process, encompassing study initiation, FDA submission, and post-marketing studies. The company's acquisition of Lincoln Technologies enhanced its capabilities, allowing it to offer comprehensive solutions for tracking and monitoring product efficacy and safety, ultimately leading to more efficient and cost-effective trial management. Prior to its acquisition by Oracle in 2010, Phase Forward was headquartered in Waltham, Massachusetts, with additional offices in the UK, Japan, France, and Australia.